Boundless Bio, Inc. (BOLD)
$2.43-4.71%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $55M
- Beta
- 0.38
- P/E (TTM)
- -0.85
- Short % float
- 4.52%
- Days to cover
- 4.3
- SI change
- -4.1%
- 1W
- -5.45%
- 1M
- -14.44%
- vs SPY 1W
- -5.31%
- vs SPY 1M
- -16.94%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on BOLD?
- LOPJLB’s latest quantitative signal on Boundless Bio, Inc. (BOLD) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BOLD in?
- Boundless Bio, Inc. (BOLD) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Boundless Bio, Inc. (BOLD) do?
- Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Pha…